Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18906874 | NOVEL GENE ARMORING | October 2024 | October 2025 | Allow | 12 | 2 | 1 | No | No |
| 18638307 | COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF IRON-RELATED DISORDERS | April 2024 | June 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18492221 | T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS | October 2023 | September 2024 | Allow | 11 | 2 | 0 | Yes | No |
| 18492310 | T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS | October 2023 | December 2024 | Abandon | 13 | 2 | 0 | Yes | No |
| 18228770 | Chimeric Antigen Receptor Therapies for Treating Solid Tumors | August 2023 | July 2025 | Allow | 24 | 3 | 1 | Yes | No |
| 18358833 | METHODS, COMPOSITIONS AND DOSING REGIMENS FOR TREATING OR PREVENTING INTERFERON-GAMMA RELATED INDICATIONS | July 2023 | January 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18339197 | IMMUNOMODULATORY FUSION PROTEINS AND USES THEREOF | June 2023 | March 2025 | Allow | 21 | 2 | 1 | No | No |
| 18174928 | METHODS OF ISOLATING T CELLS AND T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION FROM PERIPHERAL BLOOD | February 2023 | February 2026 | Allow | 36 | 0 | 0 | Yes | No |
| 18170941 | BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | February 2023 | October 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 18170969 | BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | February 2023 | November 2023 | Allow | 9 | 1 | 1 | Yes | No |
| 18169464 | Antigen Binding Molecules Targeting SARS-CoV-2 | February 2023 | December 2023 | Allow | 10 | 1 | 1 | No | No |
| 18069749 | COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS | December 2022 | December 2023 | Allow | 12 | 1 | 1 | Yes | No |
| 18066791 | IMMUNOGLOBULINS BINDING HUMAN VGAMMA9VDELTA2 T CELL RECEPTORS | December 2022 | February 2026 | Allow | 38 | 1 | 0 | Yes | No |
| 18058162 | SYNOVIAL EXTRACELLULAR MATRIX-SPECIFIC CHIMERIC ANTIGEN RECEPTOR FOR TARGETING REGULATORY T CELLS TO TREAT AUTOIMMUNE DISEASES | November 2022 | June 2023 | Allow | 7 | 0 | 1 | No | No |
| 18055950 | CD28 COMPOSITIONS AND METHODS FOR CHIMERIC ANTIGEN RECEPTOR THERAPY | November 2022 | January 2026 | Allow | 38 | 0 | 0 | No | No |
| 18055932 | COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING PSMA AND EFFECTOR CELL ANTIGENS | November 2022 | February 2026 | Allow | 39 | 1 | 0 | No | No |
| 18048621 | METHODS FOR INCREASING T-CELL FUNCTION | October 2022 | September 2023 | Allow | 10 | 0 | 1 | Yes | No |
| 18046408 | T CELL RECEPTORS | October 2022 | December 2025 | Allow | 38 | 0 | 0 | Yes | No |
| 18045946 | LIQUID FORMULATION OF HUMANIZED ANTIBODY FOR TREATING IL-6-MEDIATED DISEASES | October 2022 | March 2026 | Allow | 41 | 1 | 1 | Yes | No |
| 17948406 | METHODS FOR CONTROL OF AN INFECTIVE DISEASE WITH A VACCINE | September 2022 | December 2025 | Allow | 39 | 1 | 0 | No | No |
| 17910418 | Use of Lactoferrin | September 2022 | January 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17930662 | HUMANIZED BCMA ANTIBODY AND BCMA-CAR-T CELLS | September 2022 | September 2025 | Allow | 36 | 1 | 0 | No | No |
| 17930018 | ANTI-CD3 ANTIBODIES AND METHODS OF USE | September 2022 | June 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 17820440 | CHIMERIC ANTIGEN RECEPTORS TARGETED TO PSCA | August 2022 | October 2025 | Allow | 38 | 1 | 1 | Yes | No |
| 17795949 | ANTI-ROR1 ANTIBODIES AND COMPOSITIONS | July 2022 | September 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17795172 | CHIMERIC ANTIGEN RECEPTOR FOR RECOGNIZING FC FRAGMENT AND APPLICATION THEREOF | July 2022 | October 2025 | Allow | 38 | 0 | 1 | Yes | No |
| 17811645 | ANTIBODIES TO CD70 | July 2022 | September 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17860014 | CD127 EXPRESSION INVERSELY CORRELATES WITH FOXP3 AND SUPPRESSIVE FUNCTION OF CD4+ TREGS | July 2022 | August 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17791056 | ANTI-TNFR2 ANTIBODY AND USES THEREOF | July 2022 | January 2026 | Allow | 42 | 0 | 1 | Yes | No |
| 17854227 | LAG3 Binding Peptides | June 2022 | August 2024 | Allow | 26 | 2 | 1 | Yes | No |
| 17851944 | Antibodies to MASP-2 | June 2022 | September 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17846580 | Glycan-Interacting Compounds and Methods of Use | June 2022 | September 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17844982 | T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS | June 2022 | July 2023 | Allow | 13 | 2 | 1 | No | No |
| 17839963 | IMMUNOMODULATING TUMOR NECROSIS FACTOR RECEPTOR 25 (TNFR25) AGONISTS, ANTAGONISTS, AND IMMUNOTOXINS | June 2022 | September 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17783615 | HEAVY CHAIN ANTIBODIES BINDING TO CD38 | June 2022 | January 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17825861 | COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS | May 2022 | August 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17779711 | T CELL RECEPTORS TARGETING MUTATIONS IN RNA SPLICING FACTORS | May 2022 | January 2026 | Allow | 44 | 2 | 1 | Yes | No |
| 17774333 | ANTIBODY VARIANT COMBINATIONS AND USES THEREOF | May 2022 | February 2026 | Allow | 46 | 0 | 1 | Yes | No |
| 17771465 | ENGINEERED REGULATORY T CELL | April 2022 | March 2026 | Allow | 47 | 1 | 1 | Yes | No |
| 17723098 | SUBCUTANEOUS ADMINISTRATION OF ANTIBODIES FOR THE TREATMENT OF DISEASE | April 2022 | September 2025 | Abandon | 41 | 3 | 1 | No | No |
| 17718152 | METHODS FOR SELECTIVE EXPANSION OF GAMMA DELTA T-CELL POPULATIONS AND COMPOSITIONS THEREOF | April 2022 | March 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17703542 | MONOCLONAL ANTIBODIES AND METHODS OF USE | March 2022 | December 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17762902 | THERAPEUTIC NEUTRALIZATION ANTIBODIES FOR THE TREATMENT OF PEANUT ALLERGY | March 2022 | June 2025 | Allow | 38 | 0 | 0 | Yes | No |
| 17701283 | COMPOSITIONS COMPRISING REGULATORY T CELLS AND METHODS OF USING THE SAME | March 2022 | June 2025 | Abandon | 38 | 2 | 1 | Yes | No |
| 17700160 | HUMANIZED BCMA ANTIBODY AND BCMA-CAR-T CELLS | March 2022 | August 2022 | Allow | 5 | 1 | 0 | No | No |
| 17691565 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY | March 2022 | October 2024 | Allow | 32 | 0 | 1 | No | No |
| 17691569 | T CELL RECEPTORS RECOGNIZING HLA-A1-RESTRICTED MAGE-A3 | March 2022 | June 2025 | Allow | 39 | 2 | 1 | Yes | No |
| 17691559 | METHODS OF USING IL-21 FOR ADOPTIVE IMMUNOTHERAPY AND IDENTIFICATION OF TUMOR ANTIGENS | March 2022 | December 2024 | Abandon | 33 | 0 | 1 | No | No |
| 17638923 | IMMUNE SYNAPSE-STABILIZING CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL | February 2022 | January 2024 | Allow | 23 | 1 | 1 | Yes | No |
| 17680021 | ANTIGEN-SPECIFIC T CELL RECEPTORS AND T CELL EPITOPES | February 2022 | December 2024 | Abandon | 34 | 0 | 1 | Yes | No |
| 17753021 | Anti-VHH Domain Antibodies and Use Thereof | February 2022 | September 2025 | Allow | 43 | 1 | 1 | No | No |
| 17668134 | RADIOCONJUGATES DIRECTED TO MHC-COMPLEXED ANTIGENS IN CANCER | February 2022 | September 2024 | Abandon | 31 | 3 | 2 | Yes | No |
| 17575577 | NOVEL MODULATORS | January 2022 | March 2025 | Allow | 38 | 1 | 1 | Yes | No |
| 17561065 | METHODS, COMPOSITIONS AND DOSING REGIMENS FOR TREATING OR PREVENTING INTERFERON-GAMMA RELATED INDICATIONS | December 2021 | September 2024 | Allow | 33 | 1 | 1 | No | No |
| 17559382 | MONOCLONAL ANTIBODY AND A METHOD OF USE FOR THE TREATMENT OF LUPUS | December 2021 | February 2025 | Allow | 38 | 0 | 0 | No | No |
| 17559935 | BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA | December 2021 | August 2023 | Allow | 20 | 3 | 1 | Yes | Yes |
| 17620329 | COMBINATION THERAPY WITH CD13-TARGETED CHIMERIC PROTEINS OR CHIMERIC PROTEIN COMPLEXES | December 2021 | October 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17620148 | IMPROVEMENTS TO WASH SOLUTIONS FOR PROTEIN A CHROMATOGRAPHY IN AN ANTIBODY PURIFICATION PROCESS | December 2021 | January 2026 | Abandon | 49 | 1 | 1 | No | No |
| 17551861 | C3D CELLULAR AND ACELLULAR VACCINES FOR THE PREVENTION AND TREATMENT OF CANCER | December 2021 | October 2025 | Allow | 46 | 2 | 0 | Yes | No |
| 17551515 | PURIFIED ANTIBODY COMPOSITION | December 2021 | August 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17544539 | COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING PSMA AND EFFECTOR CELL ANTIGENS | December 2021 | August 2022 | Allow | 9 | 1 | 1 | Yes | No |
| 17615546 | APJ MODULATORS AND USES THEREOF | November 2021 | December 2025 | Abandon | 49 | 1 | 0 | No | No |
| 17535318 | ANTI-MUTATED KRAS T CELL RECEPTORS | November 2021 | January 2025 | Allow | 38 | 1 | 1 | Yes | No |
| 17528836 | T CELL WHICH EXPRESSES A GAMMA-DELTA T CELL RECEPTOR (TCR) AND A CHIMERIC ANTIGEN RECEPTOR (CAR) | November 2021 | February 2025 | Allow | 39 | 1 | 1 | No | No |
| 17610325 | REGULATORY T CELLS TARGETED BY LYMPHOTOXIN ALPHA BLOCKING AGENT AND USES THEREOF | November 2021 | July 2024 | Allow | 32 | 0 | 1 | Yes | No |
| 17516350 | BISPECIFIC BINDING MOLECULES | November 2021 | December 2024 | Allow | 37 | 0 | 0 | No | No |
| 17513621 | IMMUNOGLOBULINS BINDING HUMAN VGAMMA9VDELTA2 T CELL RECEPTORS | October 2021 | March 2022 | Allow | 4 | 0 | 1 | Yes | No |
| 17512195 | COMPOSITIONS AND METHODS FOR MODULATING DELTA GAMMA CHAIN MEDIATED IMMUNITY | October 2021 | April 2024 | Allow | 30 | 2 | 1 | Yes | No |
| 17511218 | ANTI-ALPHABETATCR ANTIBODY | October 2021 | June 2025 | Allow | 43 | 1 | 2 | Yes | No |
| 17505515 | CELLS COMPRISING NON-HLA RESTRICTED T CELL RECEPTORS | October 2021 | June 2023 | Abandon | 19 | 4 | 1 | Yes | Yes |
| 17496580 | COMPOSITIONS AND METHODS FOR USE OF RECOMBINANT T CELL RECEPTORS FOR DIRECT RECOGNITION OF TUMOR ANTIGEN | October 2021 | March 2025 | Allow | 42 | 1 | 0 | No | No |
| 17494610 | FUSION PROTEIN FOR USE IN THE TREATMENT OF HVG DISEASE | October 2021 | November 2024 | Abandon | 37 | 1 | 2 | No | No |
| 17493386 | HUMANIZED BCMA ANTIBODY AND BCMA-CAR-T CELLS | October 2021 | February 2022 | Allow | 4 | 1 | 0 | Yes | No |
| 17493685 | ENGINEERED GAMMA DELTA T-CELLS | October 2021 | March 2025 | Allow | 41 | 1 | 1 | No | No |
| 17479898 | SURROGATE CO-RECEPTORS FOR T CELLS AND METHODS OF USE | September 2021 | November 2025 | Allow | 50 | 1 | 1 | Yes | No |
| 17475686 | TCR-ENRICHED CLONOTYPE, ACQUISITION METHOD AND USE THEREOF | September 2021 | January 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17470386 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation | September 2021 | June 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17436933 | T CELL RECEPTORS AND METHODS OF USE THEREOF | September 2021 | September 2025 | Allow | 48 | 1 | 1 | No | No |
| 17463605 | T-CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS | September 2021 | August 2025 | Allow | 47 | 2 | 2 | Yes | No |
| 17400038 | ENHANCED GENERATION OF CYTOTOXIC T-LYMPHOCYTES BY IL-21 MEDIATED FOXP3 SUPPRESSION | August 2021 | August 2025 | Abandon | 48 | 2 | 1 | No | No |
| 17397656 | NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME | August 2021 | February 2025 | Abandon | 42 | 1 | 1 | Yes | No |
| 17397841 | IDENTIFICATION AND USE OF T CELL EPITOPES IN DESIGNING DIAGNOSTIC AND THERAPEUTIC APPROACHES FOR COVID-19 | August 2021 | December 2022 | Abandon | 16 | 2 | 1 | Yes | No |
| 17393682 | CD3-Binding Molecules Capable of Binding to Human and Non-Human CD3 | August 2021 | March 2024 | Allow | 31 | 1 | 0 | No | No |
| 17372070 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation | July 2021 | June 2024 | Abandon | 35 | 1 | 0 | No | No |
| 17361524 | T CELL RECEPTORS | June 2021 | November 2024 | Abandon | 41 | 1 | 1 | No | No |
| 17304924 | BCMA T CELL-ANTIGEN COUPLERS AND USES THEREOF | June 2021 | May 2022 | Allow | 11 | 1 | 1 | Yes | No |
| 17353409 | HUMAN ALPHA FETOPROTEIN-SPECIFIC T CELL RECEPTORS AND USES THEREOF | June 2021 | August 2024 | Allow | 38 | 0 | 1 | Yes | No |
| 17345425 | REDIRECTED CELLS WITH MHC CHIMERIC RECEPTORS AND METHODS OF USE IN IMMUNOTHERAPY | June 2021 | November 2024 | Abandon | 41 | 1 | 1 | No | No |
| 17338972 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | June 2021 | January 2025 | Abandon | 43 | 4 | 1 | Yes | No |
| 17327232 | BCMA-CAR-NATURAL KILLER (NK) CELLS AND METHODS RELATED THERETO | May 2021 | August 2021 | Allow | 3 | 0 | 0 | Yes | No |
| 17313761 | METHOD OF DETECTING NEW IMMUNOGENIC T CELL EPITOPES AND ISOLATING NEW ANTIGEN-SPECIFIC T CELL RECEPTORS BY MEANS OF AN MHC CELL LIBRARY | May 2021 | September 2024 | Allow | 41 | 1 | 1 | Yes | No |
| 17307351 | USE OF A CD6 BINDING PARTNER AND METHOD BASED THEREON | May 2021 | April 2025 | Abandon | 47 | 2 | 0 | No | Yes |
| 17243932 | PEPTIDES FROM NPSR1 | April 2021 | February 2024 | Abandon | 34 | 0 | 1 | No | No |
| 17290188 | BINDING DOMAIN | April 2021 | December 2024 | Allow | 44 | 1 | 0 | No | No |
| 17289690 | METHODS FOR SELECTION AND STIMULATION OF CELLS AND APPARATUS FOR SAME | April 2021 | September 2025 | Allow | 52 | 1 | 1 | No | No |
| 17287307 | T-CELL RECEPTOR CONSTANT REGION 1 ANTIBODY OR T-CELL RECEPTOR CONSTANT REGION 2 ANTIBODY | April 2021 | February 2024 | Allow | 34 | 0 | 0 | Yes | No |
| 17234726 | METHODS OF TREATING POLYCYSTIC KIDNEY DISEASE | April 2021 | June 2024 | Allow | 38 | 1 | 1 | No | No |
| 17226987 | Methods for Treating and/or Preventing Graft-Versus-Host Disease and/or Diffuse Alveolar Hemorrhage and/or Veno-Occlusive Disease Associated with Hematopoietic Stem Cell Transplant | April 2021 | October 2023 | Allow | 30 | 1 | 0 | No | No |
| 17281574 | COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED GAMMA DELTA T-CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS | March 2021 | March 2026 | Allow | 60 | 2 | 1 | Yes | No |
| 17217837 | METHODS FOR INHIBITING FIBROSIS IN A SUBJECT IN NEED THEREOF | March 2021 | October 2024 | Abandon | 42 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SKELDING, ZACHARY S.
With a 44.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 10.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SKELDING, ZACHARY S works in Art Unit 1644 and has examined 1,078 patent applications in our dataset. With an allowance rate of 55.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.
Examiner SKELDING, ZACHARY S's allowance rate of 55.9% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SKELDING, ZACHARY S receive 1.75 office actions before reaching final disposition. This places the examiner in the 38% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by SKELDING, ZACHARY S is 38 months. This places the examiner in the 29% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +52.0% benefit to allowance rate for applications examined by SKELDING, ZACHARY S. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.9% of applications are subsequently allowed. This success rate is in the 34% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 36.6% of cases where such amendments are filed. This entry rate is in the 55% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 42% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 86.2% of appeals filed. This is in the 79% percentile among all examiners. Of these withdrawals, 83.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 47.5% are granted (fully or in part). This grant rate is in the 42% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 6.2% of allowed cases (in the 88% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.3% of allowed cases (in the 64% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.